ASX Share rice
Fri 14 Aug 2020 - 11:40:am (Sydney)

ADR Share Price

ADHERIUM LIMITEDADRHealth Care Equipment & Services

ADR Company Information

Name:

Adherium Limited

Sector:

Healthcare

Industry:

Medical Devices

GIC Industry:

Health Care Technology

GIC Sub Industry:

Health Care Technology

Address:

16 Kingston Street Auckland New Zealand 1010

Phone:

64 9 307 2771

GM & Joint Company Sec.:

Mr. Rob Turnbull B.Com., C.A., B.Com, CA.

Joint Company Sec.:

Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, GAICD, GradDip CSP, FGIA

CEO & Exec. Director:

Mr. Mike Motion

Chief Financial Officer:

Ms. Anne M. Bell

Chief Technology Officer:

Mr. Geoff Feakes

Company Overview:

Adherium Limited develops, manufactures, and supplies digital health technologies that address sub-optimal medication use in chronic diseases in New Zealand, Australia, Europe, North America, and Asia. It offers Hailie, an asthma and COPD medication adherence solution for patients with chronic respiratory diseases. The company also provides a range of smart device sensors for respiratory medications, such as Bluetooth enabled Hailie sensors wrap around a patient's existing inhalers and automatically send usage data to their smartphone; and Hailie app that enables patients, caregivers, and healthcare professionals to track medication adherence, set daily reminders, and discover insights into their medication usage. It offers its digital health solutions to patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company has a collaboration with HGE Health in COPD. The company was founded in 2001 and is headquartered in Auckland, New Zealand.

ADR Share Price Information

Shares Issued:

602.41M

Market Capitalisation:

$15.06M

Revenue (TTM):

$3.21M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.068

Profit Margin:

-2.3778

Operating Margin (TTM):

$-2

Return On Assets (TTM):

$-1.02

Return On Equity (TTM):

$-30.09

Quarterly Revenue Growth (YOY):

0.435

Gross Profit(TTM):

$1.65M

Diluted Earnings Per Share (TTM):

$-0.044

ADR CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$111K

Change To Liabilities:

$-1,164,000

Total Cashflow From Investing Activities:

$111K

Net Income:

$-11,794,000

Total Cash From Operating Activities:

$-11,807,000

Depreciation:

$263K

Change To Inventory:

$114K

Change To Account Receivables:

$0.95M

Capital Expenditures:

$325K

ADR Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-11,794,000

Net Income:

$-11,794,000

Gross Profit:

$1.65M

Operating Income:

$-12,140,000

Other Operating Expenses:

$-279,000

Interest Expense:

$4K

Total Revenue:

$2.78M

Total Operating Expenses:

$13.79M

Cost Of Revenue:

$1.13M

ADR Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$92K

Total Liabilities:

$1.41M

Total Stockholder Equity:

$830K

Other Current Liabilities:

$39K

Total Assets:

$2.24M

Common Stock:

$74.35M

Other Current Assets:

$43K

Retained Earnings:

$-46,952,000

Cash:

$763K

Total Current Liabilities:

$1.41M

Property - Plant & Equipment:

$380K

Net Tangible Assets:

$738K

Total Current Assets:

$1.77M

Net Receivables:

$287K

Short-Term Investments:

$472K

Inventory:

$417K

Accounts Payable:

$0.91M

Non Currrent Assets (Other):

$472K

Short-Term Investments:

$472

Non Current Liabilities Total:

$0

ADR Share Price History

ADR News

30 Mar, 2020
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
31 Dec, 2019
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So consider...
20 Aug, 2019
Leading respiratory medical device company Adherium (ADR.AX) has unveiled its new strategic data-based initiative with Summatix Pty Ltd, with the objective of enabling clinicians globally to enhance their care of patients with asthma and chronic obstructive pulmonary disease (COPD). This follows Adherium’s post-reorganisation business model of enhancing its sensor development and platform capabilities by accessing and collaborating with leading development houses to focus on insights into how data, and its application, will impact on the practice of medicine. Adherium will be building upon its existing relationship with Summatix Pty Ltd, a private Melbourne based medical informatics company developing an open, scalable, regulated data platform to assist its clients in the dissemination and creation of actionable medical data for clinicians in the delivery of healthcare for their patients.